Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.50 |
| ▸ | GRK5 | P34947 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.48 |
| ▸ | MET | P08581 | 4/20 | 0.48 |
| ▸ | MTOR | P42345 | 3/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384703 | 0.86 | FYN (0.60) | FYNL3MBTL1KDM4EKCNH2GRK5 | |
| SCHEMBL2388135 | 0.85 | FYN (0.59) | FYNL3MBTL1KDM4EKCNH2GRK5 | |
| SCHEMBL2387014 | 0.85 | FYN (0.59) | FYNL3MBTL1KDM4EKCNH2GRK5 | |
| SCHEMBL2386761 | 0.82 | MET (0.55) | KCNH2MET | |
| SCHEMBL2383649 | 0.81 | KCNH2 (0.58) | KCNH2GRK5METATRLRRK2 | |
| SCHEMBL2384991 | 0.79 | GRK5 (0.68) | FYNGRK5ATR | |
| SCHEMBL2387884 | 0.79 | GRK5 (0.52) | FYNGRK5METATR | |
| SCHEMBL2386322 | 0.78 | GRK5 (0.78) | FYNGRK5PIK3CDATRADORA2A | |
| SCHEMBL4619233 | 0.78 | FYN (0.74) | FYNL3MBTL1KDM4EKCNH2PIK3CA | |
| SCHEMBL2749343 | 0.77 | FYN (0.62) | FYNL3MBTL1KDM4EKCNH2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | FYN 1193/4885L3MBTL1 4648/4885KDM4E 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.